A Phase 4 interventional study of Blood sample and Radiography in Growth Hormone Deficiency, sponsored by Pfizer. Completed at 8 sites in France. Open to participants aged 4 Years to 11 Years. Per ClinicalTrials.gov, last updated 2007-06-06.
Sponsored by Pfizer · Phase 4, Interventional, and Treatment
To assess the predictive value of the short term IGF-1 stimulation test, based on IGF-1 changes, on the 24 months growth response to 2 different doses of GH in patients with conventional GH deficiency.
164 studies on the registry are indexed under Dwarfism, Pituitary; 25 are open to participants now.
This study's enrollment of 82 is above the median of 72 across 122 interventional studies indexed under Dwarfism, Pituitary.
Browse Dwarfism, Pituitary studies →Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Change of height standard deviation score after 24 months of treatment according to the short term response of plasma IGF1 to Genotonorm.
This study is completed, as verified in May 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer